Trial NCT04649021
Publication Hui A-M, Lancet, 2022
Primary outcome on the report: 1) Geometric mean titers (GMTs) against live SARS-CoV-2 and 2) the seroconversion rate (SCR), measured one month after the second dose compared to baseline.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.